Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

G3 Completes GLOBAL Study Patient Enrollment

Published: Thursday, February 13, 2014
Last Updated: Monday, February 17, 2014
Bookmark and Share
Pilot data of single largest prospective pan-omic study to identify key biomarkers and central therapeutic targets for cardiovascular diseases.

Global Genomics Group (G3) announce that it has completed enrollment of the 5,000-patient discovery cohort of its GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) clinical study. Pilot data for the first cohort of patients are expected later this year.

The GLOBAL study, designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis, enrolled 5,000 patients in the discovery group, with approximately 2,500 patients in the control group and approximately 2,500 patients in the case group. Precision phenotyping is conducted with cardiovascular computed tomography (CT), including calcium scoring and CT angiography, an advanced, non-invasive imaging technology. A pan-omic analysis that includes whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics and lipidomics, will be conducted for every patient. The data will be analyzed with systems biology driven bioinformatics.

"The strong interest and support from the medical community has allowed us to rapidly enroll patients at many of the top centers worldwide, and we are well ahead of our original schedule," said Bradley Brown, co-founder and vice president of clinical affairs of G3. "This is an important milestone for G3 as well as for our collaborating researchers and participating patients. The GLOBAL study will allow us to gain important insights about the development of cardiovascular disease and to identify new disease biomarkers and therapeutic targets. We anticipate that the pilot data set will be available later this year."

The GLOBAL study is enrolling patients at 48 institutions in 9 countries and across three continents. The investigators anticipate enrolling an additional 2,000 patients in the validation cohort, with approximately 1,000 patients in the disease group and 1,000 in the control group.

Stephen Bloom, M.D., of Midwest Heart & Vascular Specialists, Kansas City, Mo., a principal investigator of the study, said, "Cardiovascular disease remains the leading cause of death worldwide, and the biological pathways leading to atherosclerosis — the primary reason for heart attacks and stroke — remain largely unknown. The GLOBAL study is the most ambitious study ever undertaken to investigate the root cause of this complex disease and may not only provide us with new biomarkers and drug targets, but it will also provide us with a platform for early screening, continued monitoring of risk, prevention and early intervention."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

G3, Caprion Partner on Global Cardiovascular Disease Biomarker Study
Caprion to identify blood-based protein markers for study.
Wednesday, February 26, 2014
Scientific News
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
NIH Study Finds Link Between Depression, Gestational Diabetes
Researchers at NIH have discovered that the depression in early pregnancy doubles risk for gestational diabetes, and gestational diabetes increases risk for postpartum depression.
Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
Researcher have discovered that harm caused by pathogens in the intestinal tract benefit from immune system response to damaged intestinal lining.
Cancer's Taste for Fat
Researchers discovered signalling pathway for fat burning is disrupted in certain cancers.
‘Tracking Bugs’ Reveal Secret of Cancer Cell Metabolism
Unexpected finding shows instead of throwing away valuable nutrients, the cells squeeze out every last drop of energy.
Ginger Nano-Lipid Particles May Improve Cancer Treatment
Edible ginger-derived nano-lipids show promise for effectively targeting and delivering chemotherapeutic drugs used to treat colon cancer.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
Absolute Quantification of Mitochondrial Metabolites
Scientists have developed a method to quickly isolate and systematically measure metabolite concentrations within mitochondria.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!